Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
China GLP-1 Receptor Agonist Market Analysis and Trends China represents a major emerging market, driven by an increasing diabetes burden, expanding healthcare access, and supportive government initiatives
Notably, between 2019 and 2022, the rate of increase was particularly steep
A clinical trial in over 600 patients with type 2 diabetes assessed the effect of lorcaserin on weight loss and metabolic parameters
Known type 2 diabetes mellitus agents such as metformin, thiazolidinediones (TZDs), sulfonylureas, or basal insulin may also be considered
Recent developments: April 2026, The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, potentially limiting large-scale compounding activities
J Biol Chem 270:1567515685
US$ 28.69
US$ 24.80
US$ 23.70
US$ 29.64
US$ 20.16
US$ 26.58
US$ 28.67
US$ 23.69
US$ 21.45
US$ 24.82
.jpg)
